American Shared Hospital Services (NYSE American: AMS), a provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services, announced today that it will release its first quarter 2026 financial results before the market opens on May 14, 2026. The company will hold a conference call at 12:00 p.m. ET that same day to discuss the results, offering investors and analysts insight into its performance and strategic direction.
The call comes as the company continues to expand its footprint in North and South America through turnkey solutions for cancer treatment centers, health systems, and cancer networks. American Shared Hospital Services works closely with partners to develop and grow their cancer service lines, providing integrated cancer care in local settings. For centers under health system partnerships, the company and its partners share capital investment costs and profitability based on ownership interests. This model has positioned AMS as a key player in the growing market for advanced radiation therapy, including Gamma Knife and proton therapy services.
To participate in the conference call, domestic callers may dial 1-844-413-3972 and international callers may dial 1-412-317-5776 at least 10 minutes prior to the start of the call. A simultaneous webcast will be accessible through the company's website at www.ashs.com or directly via this link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=NAuZg0I8. A replay of the call will be available from May 14 through May 21, 2026, by dialing 1-855-669-9658 or 1-412-317-0088, access code 6753554. The replay will also be archived on the company's website.
The earnings release is expected to provide updates on the company's financial health and its progress in the advanced radiation therapy and cancer treatment services segments. The company's forward-looking statements, as outlined in its Safe Harbor statement, highlight risks including economic conditions, compliance with debt covenants, variability of financial results between quarters, and changes to CMS reimbursement rates. Additionally, the expansion of Gamma Knife, proton therapy, and advanced radiation therapy businesses involves risks related to timing, financing, and operations in new markets. The integration or continued operation of acquired businesses could also affect financial results.
For leaders in the business and technology sectors, this announcement underscores the growing importance of cancer treatment technology and the financial dynamics of healthcare service providers. As AMS navigates market conditions and reimbursement changes, its performance may serve as a bellwether for the broader radiation therapy equipment leasing and patient care services industry. The company's focus on partnerships and shared risk models could offer insights into sustainable growth strategies in healthcare.
Investors and industry watchers will be keen to hear management's commentary on the first quarter results and outlook for the remainder of 2026. The call provides an opportunity to assess how the company is managing the risks outlined in its SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2025. With a market presence in the Americas and a commitment to expanding cancer care access, American Shared Hospital Services remains a company to watch in the evolving landscape of radiation oncology.
